ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 131 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q2 2022. The put-call ratio across all filers is 0.47 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $5,005,192 | -17.8% | 205,552 | +13.9% | 0.00% | -50.0% |
| Q1 2024 | $6,092,040 | +644.4% | 180,398 | +595.1% | 0.00% | – |
| Q4 2023 | $818,330 | +37.8% | 25,954 | +11.6% | 0.00% | – |
| Q3 2023 | $593,961 | +46.7% | 23,247 | +37.6% | 0.00% | – |
| Q2 2023 | $404,974 | 0.0% | 16,895 | 0.0% | 0.00% | – |
| Q1 2023 | $404,974 | -99.9% | 16,895 | -4.5% | 0.00% | – |
| Q1 2022 | $476,976,000 | -27.2% | 17,692 | 0.0% | 0.00% | – |
| Q4 2021 | $654,781,000 | -27.7% | 17,692 | -6.6% | 0.00% | – |
| Q3 2021 | $905,192,000 | +43.2% | 18,945 | +1.4% | 0.00% | – |
| Q2 2021 | $631,996,000 | -5.7% | 18,676 | +15.1% | 0.00% | – |
| Q1 2021 | $670,093,000 | +5.8% | 16,225 | +11.1% | 0.00% | – |
| Q4 2020 | $633,348,000 | +3.2% | 14,600 | +2.1% | 0.00% | – |
| Q3 2020 | $613,470,000 | +18.2% | 14,300 | +28.8% | 0.00% | – |
| Q2 2020 | $518,814,000 | – | 11,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Portolan Capital Management | 484,907 | $11,807,485 | 0.97% |
| Nikko Asset Management Americas, Inc. | 1,563,065 | $37,966,849 | 0.44% |
| Diametric Capital, LP | 32,765 | $797,827 | 0.43% |
| ARK Investment Management | 1,964,964 | $47,846,871 | 0.42% |
| SummerHaven Investment Management, LLC | 23,400 | $569,790 | 0.38% |
| Quantedge Capital Pte Ltd | 40,800 | $993,480 | 0.36% |
| Granahan Investment Management | 344,549 | $8,389,768 | 0.34% |
| FEDERATED HERMES, INC. | 4,694,060 | $114,300,361 | 0.27% |
| Belmont Capital, LLC | 40,000 | $974,000 | 0.18% |
| Woodline Partners LP | 754,023 | $18,360,460 | 0.18% |